Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 35c; offers guidance

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.68, $0.35 better than the analyst estimate of $0.33. Revenue for the quarter came in at $148.4 million versus the consensus estimate of $136.37 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2025 revenue of $565-585 million, versus the consensus of $562.1 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.

You May Also Be Interested In

• Goldman Equities Haul To Rip Past $5 Billion Toward New Record - Bloomberg
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Bernstein SocGen's Thoughts on Abbvie (ABBV) Following APGE Acquisition